|1.||Tsukimura, Takahiro: 5 articles (07/2015 - 07/2010)|
|2.||Togawa, Tadayasu: 5 articles (07/2015 - 07/2010)|
|3.||Sakuraba, Hitoshi: 5 articles (07/2015 - 07/2010)|
|4.||Auray-Blais, Christiane: 4 articles (07/2015 - 12/2010)|
|5.||Linthorst, Gabor E: 4 articles (03/2013 - 01/2011)|
|6.||Boutin, Michel: 3 articles (07/2015 - 12/2012)|
|7.||Breunig, Frank: 3 articles (02/2014 - 01/2011)|
|8.||Wanner, Christoph: 3 articles (02/2014 - 01/2011)|
|9.||Hwu, Wuh-Liang: 3 articles (09/2013 - 12/2010)|
|10.||Mascher, Hermann: 3 articles (09/2013 - 01/2013)|
|1.||Heart Diseases (Heart Disease)
07/20/2015 - "The lyso-Gb3 analog at m/z 836 was found at increased levels only in patients manifesting clinically severe heart disease, irrespective of the pathogenicity of the GLA variant they carried. "
07/20/2015 - "This finding suggests that this lyso-Gb3 analog might be an earlier biomarker of progressive heart disease, non-specific of the FD cardiomyopathy. "
01/01/2015 - "After switching to agalsidase alfa with standard care in heart disease, BNP level, echocardiographic parameters, eGFR rate and lyso-Gb3 levels were improved or stabilized. "
|2.||Fabry Disease (Fabry's Disease)
01/01/2015 - "This study also revealed that not only lyso-Gb3 but also lyso-Gb3(-2) in plasma is a useful biomarker for the diagnosis of Fabry disease. "
12/25/2015 - "Recently, an increased plasma level of lyso-Gb3 was suggested as a new biomarker in Fabry disease. "
10/15/2015 - "Lyso-Gb3 accumulates in serum in Fabry disease and increases extracellular matrix synthesis in podocytes. "
07/01/2015 - "Electron microscopic examination revealed numerous membranous inclusion bodies in podocytes, and biochemical analysis revealed normal GLA activity and a normal lyso-Gb3 level in plasma, showing that they did not have Fabry disease. "
01/01/2015 - "Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease."
05/06/2015 - "We investigated the link between Gb3, lyso-Gb3 and pain. "
01/01/2011 - "In addition, plasma lysoGb3, eGFR, quality of life (SF-36) and brief pain inventory (BPI) questionnaires were analysed. "
05/06/2015 - "These studies suggest a direct role for lyso-Gb3 in the sensitisation of peripheral nociceptive neurons that may provide an opportunity for therapeutic intervention in the treatment of Fabry disease-associated pain."
05/06/2015 - "The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain."
01/01/2015 - "This study suggested that increased plasma lyso-Gb3 has a crucial role in the development of renal fibrosis through the cell-specific induction of the EMT in Fabry disease, and that TRI treatment, alongside enzyme replacement therapy, could be a potential therapeutic option for patients with Fabry disease. "
|5.||Aortic Aneurysm (Aneurysm, Aortic)
|2.||Biological Markers (Surrogate Marker)
|5.||Protein Isoforms (Isoforms)
|6.||Calcitriol Receptors (Calcitriol Receptor)
|1.||Enzyme Replacement Therapy